Insmed Incorporated (NASDAQ:INSM) finished Thursday with a subtraction of -$0.25 to close at $22.47, a downside of -1.10 percent. An average of 1,500,217 shares of common stock have been traded in the last five days. There was a gain of $0.47 in the past week, and it reached a new high 2 times over the past 12 months. The last 20 days have seen an average of 1,254,774 shares traded, while the 50-day average volume stands at 1,068,652.
INSM stock has increased by 7.16% in the last month. The company shares reached their 1-month lowest point of $20.01 on 07/12/23. With the stock rallying to its 52-week high on 08/10/23, shares of the company touched a low of $16.04 and a high of $28.10 in 52 weeks. It has reached a new high 9 times so far this year and achieved 12.47% or $2.48 in price. In spite of this, the price is down -20.03% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
INSM stock investors should be aware that Insmed Incorporated (INSM) stock had its last reported insider trading activity 31 days ago on Jul 11. In this transaction, the insider spent $14,933. Chief Operating Officer, Adsett Roger, disposed of 8,981 shares at a price of $19.32 on Jun 13. The insider now owns more than $173,513 worth of shares. Prior to that, Chief Medical Officer Flammer Martina M.D. went on to Sale 8,868 shares at $19.27 each on Jun 13. An amount of $170,886 was transacted.
Valuation Metrics
Insmed Incorporated (INSM) stock’s beta is 1.54. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 11.99.
Financial Health
The quick ratio of Insmed Incorporated for the three months ended June 29 was 4.80, and the current ratio was 5.20, indicating that the company is able to meet its debt obligations. Insmed Incorporated’s EBITDA margin for the year ending June 29 is -184.98%. Its gross profit as reported stood at $190.23 million compared to revenue of $245.36 million.
Earnings Surprise
For the three-month period that ended June 29, Insmed Incorporated had $304.89 million in cash and short-term investments compared to $1.14 billion in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$244.81 million in the quarter, while revenues of -$159.76 million were grew 60.93%. The analyst consensus anticipated Insmed Incorporated’s latest quarter earnings to come in at -$1.13 per share, but it turned out to be -$1.78, a -57.50% surprise. For the quarter, EBITDA amounted to -$230.27 million. Shareholders own equity worth $143.8 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Insmed Incorporated (INSM) price momentum. RSI 9-day as of the close on 10 August was 62.47%, suggesting the stock is Neutral, with historical volatility in this time frame at 34.93%.
As of today, INSM’s price is $22.12 +2.11% or $0.47 from its 5-day moving average. INSM is currently trading +9.00% higher than its 20-day SMA and +31.93% higher than its 100-day SMA. However, the stock’s current price level is +18.00% above the SMA50 and +32.01% above the SMA200.
The stochastic %K and %D were 75.42% and 71.74%, respectively, and the average true range (ATR) was 0.80. With the 14-day stochastic at 81.21% and the average true range at 0.76, the RSI (14) stands at 61.67%. The stock has reached 0.16 on the 9-day MACD Oscillator while the 14-day reading was at 0.58.
Analyst Ratings
Guggenheim launched coverage on Insmed Incorporated (NASDAQ: INSM) in its analyst report released on July 26, 2023. The firm assigned the stock a Buy rating. The consensus rating for Insmed Incorporated (INSM) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell INSM, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 1 analysts, while 12 others rate it as a “buy”.
What is INSM’s price target for the next 12 months?
Analysts predict a range of price targets between $30.00 and $52.00, with a median target of $41.00. Taking a look at these predictions, the average price target given by analysts for Insmed Incorporated (INSM) stock is $40.77.
